These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 20649626

  • 21. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.
    Hollstein T, Vogt A, Grenkowitz T, Stojakovic T, März W, Laufs U, Bölükbasi B, Steinhagen-Thiessen E, Scharnagl H, Kassner U.
    Vascul Pharmacol; 2019 May; 116():8-15. PubMed ID: 30910670
    [Abstract] [Full Text] [Related]

  • 22. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels.
    Troutt JS, Alborn WE, Cao G, Konrad RJ.
    J Lipid Res; 2010 Feb; 51(2):345-51. PubMed ID: 19738285
    [Abstract] [Full Text] [Related]

  • 23. Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials.
    Sahebkar A, Simental-Mendía LE, Guerrero-Romero F, Golledge J, Watts GF.
    Diabetes Obes Metab; 2015 Nov; 17(11):1042-55. PubMed ID: 26183252
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.
    Chan DC, Watts GF, Somaratne R, Wasserman SM, Scott R, Barrett PHR.
    Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1644-1655. PubMed ID: 29880491
    [Abstract] [Full Text] [Related]

  • 26. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
    Constantinides A, Kappelle PJ, Lambert G, Dullaart RP.
    Arch Med Res; 2012 Jan; 43(1):11-4. PubMed ID: 22300679
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia.
    Dijk W, Cariou B.
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 1():39-51. PubMed ID: 31002456
    [Abstract] [Full Text] [Related]

  • 29. Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.
    Zhu YM, Anderson TJ, Sikdar K, Fung M, McQueen MJ, Lonn EM, Verma S.
    Arterioscler Thromb Vasc Biol; 2015 Oct; 35(10):2254-9. PubMed ID: 26293463
    [Abstract] [Full Text] [Related]

  • 30. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.
    Ouguerram K, Chetiveaux M, Zair Y, Costet P, Abifadel M, Varret M, Boileau C, Magot T, Krempf M.
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1448-53. PubMed ID: 15166014
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects.
    Taskinen MR, Björnson E, Andersson L, Kahri J, Porthan K, Matikainen N, Söderlund S, Pietiläinen K, Hakkarainen A, Lundbom N, Nilsson R, Ståhlman M, Adiels M, Parini P, Packard C, Borén J.
    J Clin Lipidol; 2020 Aug; 14(1):77-87. PubMed ID: 31917184
    [Abstract] [Full Text] [Related]

  • 33. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol.
    Alborn WE, Cao G, Careskey HE, Qian YW, Subramaniam DR, Davies J, Conner EM, Konrad RJ.
    Clin Chem; 2007 Oct; 53(10):1814-9. PubMed ID: 17702855
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment.
    Chan DC, Wong AT, Yamashita S, Watts GF.
    Atherosclerosis; 2012 Apr; 221(2):484-9. PubMed ID: 22341868
    [Abstract] [Full Text] [Related]

  • 36. PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism.
    Bridge SH, Sheridan DA, Felmlee DJ, Crossey MM, Fenwick FI, Lanyon CV, Dubuc G, Seidah NG, Davignon J, Thomas HC, Taylor-Robinson SD, Toms GL, Neely RD, Bassendine MF.
    J Hepatol; 2015 Apr; 62(4):763-70. PubMed ID: 25463543
    [Abstract] [Full Text] [Related]

  • 37. Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors.
    Leander K, Mälarstig A, Van't Hooft FM, Hyde C, Hellénius ML, Troutt JS, Konrad RJ, Öhrvik J, Hamsten A, de Faire U.
    Circulation; 2016 Mar 29; 133(13):1230-9. PubMed ID: 26896437
    [Abstract] [Full Text] [Related]

  • 38. Circulating PCSK9 is a strong determinant of plasma triacylglycerols and total cholesterol in homozygous carriers of apolipoprotein ε2.
    Brouwers MC, van Greevenbroek MM, Konrad RJ, Troutt JS, Schaper NC, Stehouwer CD.
    Clin Sci (Lond); 2014 May 29; 126(9):679-84. PubMed ID: 24308640
    [Abstract] [Full Text] [Related]

  • 39. Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state.
    Chan DC, Wong AT, Pang J, Barrett PH, Watts GF.
    Clin Sci (Lond); 2015 Mar 29; 128(6):379-85. PubMed ID: 25291660
    [Abstract] [Full Text] [Related]

  • 40. Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people.
    Sullivan S, Fabbrini E, Horton JD, Korenblat K, Patterson BW, Klein S.
    Transl Res; 2011 Nov 29; 158(5):302-6. PubMed ID: 22005270
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.